These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 27133742)

  • 1. Nintedanib (BIBF 1120) blocks the tumor promoting signals of lung fibroblast soluble microenvironment.
    Epstein Shochet G; Israeli-Shani L; Koslow M; Shitrit D
    Lung Cancer; 2016 Jun; 96():7-14. PubMed ID: 27133742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nintedanib in non-small cell lung cancer: from preclinical to approval.
    Caglevic C; Grassi M; Raez L; Listi A; Giallombardo M; Bustamante E; Gil-Bazo I; Rolfo C
    Ther Adv Respir Dis; 2015 Aug; 9(4):164-72. PubMed ID: 25855060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Angiogenics: Their Value in Lung Cancer Therapy.
    Janning M; Loges S
    Oncol Res Treat; 2018; 41(4):172-180. PubMed ID: 29631257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nintedanib for the treatment of non-small-cell lung cancer.
    Rashdan S; Hanna N
    Expert Opin Pharmacother; 2014 Apr; 15(5):729-39. PubMed ID: 24597846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nintedanib, a novel triple angiokinase inhibitor for the treatment of non-small cell lung cancer.
    Noonan S; Man Wong K; Jimeno A
    Drugs Today (Barc); 2015 Jun; 51(6):357-66. PubMed ID: 26261849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases.
    Hilberg F; Tontsch-Grunt U; Baum A; Le AT; Doebele RC; Lieb S; Gianni D; Voss T; Garin-Chesa P; Haslinger C; Kraut N
    J Pharmacol Exp Ther; 2018 Mar; 364(3):494-503. PubMed ID: 29263244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology.
    Dhillon S
    Target Oncol; 2015 Jun; 10(2):303-10. PubMed ID: 25894578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BIBF 1120/ nintedanib : a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer.
    Rolfo C; Raez LE; Bronte G; Santos ES; Papadimitriou K; Buffoni L; van Meerbeeck JP; Russo A
    Expert Opin Investig Drugs; 2013 Aug; 22(8):1081-8. PubMed ID: 23790097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BIBF 1120 for the treatment of non-small cell lung cancer.
    Reck M
    Expert Opin Investig Drugs; 2010 Jun; 19(6):789-94. PubMed ID: 20465363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells.
    Nishijima N; Seike M; Soeno C; Chiba M; Miyanaga A; Noro R; Sugano T; Matsumoto M; Kubota K; Gemma A
    Int J Oncol; 2016 Mar; 48(3):937-44. PubMed ID: 26783187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer.
    Skouras VS; Maragkos C; Grapsa D; Syrigos KN
    BioDrugs; 2016 Oct; 30(5):421-439. PubMed ID: 27670779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis.
    Hostettler KE; Zhong J; Papakonstantinou E; Karakiulakis G; Tamm M; Seidel P; Sun Q; Mandal J; Lardinois D; Lambers C; Roth M
    Respir Res; 2014 Dec; 15(1):157. PubMed ID: 25496490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
    Kurzrock R; Stewart DJ
    Clin Cancer Res; 2017 Mar; 23(5):1137-1148. PubMed ID: 27940520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation the crosstalk between tumor-associated macrophages and non-small cell lung cancer to inhibit tumor migration and invasion by ginsenoside Rh2.
    Li H; Huang N; Zhu W; Wu J; Yang X; Teng W; Tian J; Fang Z; Luo Y; Chen M; Li Y
    BMC Cancer; 2018 May; 18(1):579. PubMed ID: 29783929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting tumor neovasculature in non-small-cell lung cancer.
    Pallis AG; Syrigos KN
    Crit Rev Oncol Hematol; 2013 May; 86(2):130-42. PubMed ID: 23159217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting angiogenesis in squamous non-small cell lung cancer.
    Piperdi B; Merla A; Perez-Soler R
    Drugs; 2014 Mar; 74(4):403-13. PubMed ID: 24578213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions.
    Ellis PM; Al-Saleh K
    Crit Rev Oncol Hematol; 2012 Oct; 84(1):47-58. PubMed ID: 22405734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer.
    Kutluk Cenik B; Ostapoff KT; Gerber DE; Brekken RA
    Mol Cancer Ther; 2013 Jun; 12(6):992-1001. PubMed ID: 23729403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Antiangiogenetic Therapy Beyond Bevacizumab in the Treatment of Advanced Non Small Cell Lung Cancer.
    Sacco PC; Maione P; Rossi A; Sgambato A; Casaluce F; Palazzolo G; Gridelli C
    Curr Pharm Des; 2015; 21(32):4763-72. PubMed ID: 26219615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.
    Nikolinakos PG; Altorki N; Yankelevitz D; Tran HT; Yan S; Rajagopalan D; Bordogna W; Ottesen LH; Heymach JV
    Cancer Res; 2010 Mar; 70(6):2171-9. PubMed ID: 20215520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.